A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Efprezimod alfa (Primary)
- Indications COVID-19 respiratory infection; Respiratory insufficiency
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SAC-COVID
- Sponsors OncoImmune
- 01 May 2022 Primary endpoint (Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status) has been met as per results published in The Lancet Infectious Diseases
- 01 May 2022 Results published in The Lancet Infectious Diseases
- 15 Apr 2021 According to a Merck and Co media release, given timeline and these technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Mercks resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck has determined to discontinue development of MK-7110 for COVID-19.